Najla H. Al Ali

Eprenetapopt (APR-246) and Azacitidine in <i>TP53</i>-Mutant Myelodysplastic Syndromes

David A. Sallman, Amy E. DeZern, Guillermo Garcia‐Manero et al. · Journal of Clinical Oncology · 2021 · 460 citations · Full text

Medicine, Oncology, Pharmacology +5

Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes

David A. Sallman, Rami S. Komrokji, Christine Vaupel et al. · Leukemia · 2015 · 231 citations · Full text

Life Sciences, Genetics, Molecular Genetics +14

<i>TP53</i> mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype

David A. Sallman, Amy F. McLemore, Amy L. Aldrich et al. · Blood · 2020 · 188 citations · Full text

Medicine, Hematology, Molecular Genetics +13

An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies

Eric Padron, Guillermo Garcia‐Manero, Mrinal M. Patnaik et al. · Blood Cancer Journal · 2015 · 140 citations · Full text

Medicine, Clinical Sciences, Oncology +14

Autoimmune diseases and myelodysplastic syndromes

Rami S. Komrokji, Austin Kulasekararaj, Najla H. Al Ali et al. · American Journal of Hematology · 2016 · 133 citations · Full text

Medicine, Hematology, Immunology +9